Obesity Market Size and Share Analysis

Market Overview:

The 7 major obesity markets reached a value of USD 25.8 Billion in 2024. Looking forward, the 7MM are expected to reach USD 150.2 Billion by 2035, exhibiting a growth rate (CAGR) of 17.5% during 2025-2035. The market's expansion is significantly influenced by the introduction of highly effective novel therapies and a growing patient population, with the United States currently holding the largest market share.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2035
Historical Years	2019-2024
Market Size in 2024	USD 25.8 Billion
Market Forecast in 2035	USD 150.2 Billion
Market Growth Rate 2025-2035	17.5%

The obesity market has been comprehensively analyzed in this new report titled "Obesity Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Obesity is a complex, chronic disease characterized by excessive body fat accumulation that presents a risk to health. The World Health Organization (WHO) defines overweight and obesity as abnormal or excessive fat accumulation that may impair health, with a body mass index (BMI) of 30 or above generally considered obese. The condition increases the risk of numerous health problems, including type 2 diabetes, cardiovascular diseases, hypertension, certain cancers, and musculoskeletal disorders. Diagnosis involves calculating BMI, measuring waist circumference, and assessing for the presence of comorbidities. Blood tests to check cholesterol, blood sugar, and liver function may also be conducted to evaluate the overall health impact.

The global obesity market is experiencing unprecedented growth, driven primarily by the rising global prevalence of obesity and associated comorbidities. A major catalyst for this expansion is the recent launch and widespread adoption of highly effective novel drug classes, particularly GLP-1 receptor agonists like semaglutide and tirzepatide, which have demonstrated significant weight loss benefits. This has shifted the treatment paradigm from lifestyle management and older, less effective drugs to potent pharmacological interventions. Furthermore, increasing awareness among both patients and healthcare providers about obesity as a treatable medical condition, rather than a lifestyle choice, is boosting diagnosis and treatment rates. Government and public health initiatives aimed at curbing the obesity epidemic are also contributing to market growth. Additionally, the robust pipeline of next-generation therapies, including oral formulations and combination drugs targeting multiple metabolic pathways, promises to sustain strong market growth and address unmet needs for safer, more convenient, and more effective treatments in the coming years.

Market Trends and Analysis

A key trend shaping the obesity market is the dominance of incretin-based therapies. Drugs like GLP-1 and dual GIP/GLP-1 receptor agonists are setting new standards for efficacy, leading to a decline in the market share of older medications. Another significant trend is the focus on developing oral anti-obesity medications, which could improve patient compliance and accessibility compared to current injectable options. There is also a growing emphasis on personalized medicine, with research underway to identify biomarkers that can predict a patient's response to specific therapies. Digital health platforms, including apps for tracking diet, exercise, and medication adherence, are increasingly being integrated into weight management programs, representing another key market trend.

Market Segmentation

The obesity market is segmented by:

• Drug Class: GLP-1 Receptor Agonists, Dual GIP/GLP-1 Receptor Agonists, Lipase Inhibitors, and others. The GLP-1 and dual-agonist classes currently dominate the market in terms of sales and are expected to continue this trend.
• Route of Administration: The market is primarily composed of injectable therapies, but the development of oral formulations is a key area of focus that is expected to capture significant market share in the forecast period.
• Distribution Channel: The primary channels include hospital pharmacies, retail pharmacies, and online pharmacies, with retail pharmacies holding the largest share due to the chronic nature of treatment.

Regional Outlook

The United States dominates the 7MM obesity market due to a high prevalence of obesity, greater patient awareness, favorable reimbursement policies for new therapies, and high healthcare expenditure. The EU5 (Germany, France, UK, Italy, Spain) region represents the second-largest market, with growth driven by increasing obesity rates and the gradual approval and adoption of novel treatments. Japan's market is also expected to grow, although at a slower pace, influenced by specific regulatory pathways and a different BMI classification for obesity.

Recent Developments:

In February 2025, Eli Lilly and Company announced that the FDA granted Fast Track designation for its investigational oral GLP-1 agonist, Orforglipron, for the treatment of obesity. This designation is expected to accelerate the review process for the drug, which aims to provide a convenient, once-daily pill alternative to injectable therapies.

In December 2024, Novo Nordisk presented new data from a Phase 3b trial for CagriSema (a combination of semaglutide and cagrilintide). The results showed superior weight loss compared to semaglutide alone, highlighting the potential of combination therapies to further enhance treatment efficacy in individuals with obesity.

In October 2024, Amgen announced the initiation of its Phase 3 clinical trial program for MariTide (maridebart cafraglutide), an antibody-peptide conjugate administered monthly. The program will evaluate its efficacy and safety across a broad population of overweight and obese patients, with and without type 2 diabetes.

Emerging and In-Market Drugs:

Wegovy (Semaglutide) is a GLP-1 receptor agonist developed by Novo Nordisk. Administered as a once-weekly subcutaneous injection, it works by mimicking the incretin hormone GLP-1 to regulate appetite and food intake, leading to reduced calorie consumption and significant weight loss. It is a market-leading therapy for chronic weight management.

Zepbound (Tirzepatide), from Eli Lilly and Company, is a dual GIP and GLP-1 receptor agonist. By activating both of these incretin pathways, it provides a powerful, synergistic effect on appetite control and glucose metabolism, resulting in substantial weight loss. It is administered as a once-weekly injection and has demonstrated superior efficacy in clinical trials compared to GLP-1 agonists alone.

Retatrutide (LY3437943) is an investigational triple-agonist receptor targeting GIP, GLP-1, and glucagon, currently in late-stage development by Eli Lilly and Company. By engaging all three pathways involved in energy balance and metabolism, Retatrutide has shown unprecedented levels of weight loss in mid-stage clinical trials, positioning it as a potentially transformative future therapy for obesity.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the obesity market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the obesity market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current obesity marketed drugs and late-stage pipeline drugs. The market is currently dominated by a few key players, but the pipeline is rich with candidates from both established pharmaceutical giants and emerging biotech companies.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Anticipated Market Performance

Drug/Pipeline Candidate	Company Name
Wegovy (Semaglutide)	Novo Nordisk
Zepbound (Tirzepatide)	Eli Lilly and Company
Saxenda (Liraglutide)	Novo Nordisk
Qsymia (Phentermine/topiramate)	VIVUS
Contrave (Bupropion/naltrexone)	Currax Pharma
Retatrutide (LY3437943)	Eli Lilly and Company
MariTide (Maridebart cafraglutide/AMG 133)	Amgen
Orforglipron (LY3502970)	Eli Lilly and Company
Survodutide (BI 456906)	Boehringer Ingelheim/Zealand Pharma
CagriSema	Novo Nordisk

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the obesity market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the obesity market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the obesity market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market, such as muscle mass preservation and long-term affordability?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of obesity across the seven major markets?
• What is the number of prevalent cases (2019-2035) of obesity by age and gender across the seven major markets?
• What is the number of prevalent cases by BMI class (Class I, II, and III) across the 7MM?
• How many patients are diagnosed and treated (2019-2035) with obesity across the seven major markets?
• What is the size of the obesity patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of obesity?

Obesity: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance and sales forecasts?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How do the efficacy and safety profiles of emerging therapies compare to current standards of care?
• What are the current treatment guidelines for obesity management across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, and collaborations in the obesity market?
• What is the clinical trial landscape for obesity therapies, including trial status, phase, and endpoints?